Clinical

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses how small molecule inhibitors are used in atopic dermatitis, as well as why there is no one-size-fits approach to implementing them in practice.

Several biomarkers identified by comprehensive genomic profiling were found to predict efficacy and toxicity of chemo-radiotherapy in patients with non–small cell lung cancer (NSCLC), with progression-free survival and overall survival outcomes associated with some of the identified genes.

Two experts examine how the biosimilar programs at their organization were created and the initial goals they had in mind.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the increased use of biosimilars, including successes and challenges and the process of transitioning to biosimilars at their organizations.

With no single biomarker for systemic lupus erythematosus, investigators wanted to investigate whether there is a connection between mean platelet volume and the disease.

Most early glucocorticoid treatment was targeted to patients with the most severe or active disease, according to study results from Canada.

As spinal muscular atrophy (SMA) treatments advance, new biomarkers that correlate with clinical outcomes are needed to gauge treatment response.

Multiple comorbidities and medications are prevalent in older cancer populations, who may benefit from structured medication reviews by specialist geriatricians.

Two posters presented at AMCP Nexus 2021 analyzed the costs of treating cytokine release syndrome and neurological events, 2 common adverse events (AEs) of chimeric antigen receptor (CAR) T-cell therapy.

A new analysis suggests physicians should be on the lookout for cardiovascular disease and other types of cancer, in addition to acute myeloid lymphom, when caring for patients with certain myeloproliferative neoplasms (MPNs).

Patients with axial spondyloarthritis treated with secukinumab achieved a reduction in spinal pain and improved disease activity measures early in treatment.

Early diagnosis of Fabry disease is essential and that since symptoms depend on the type of disease and sex and age of the patient, a high-risk screening system should account for the age of the target population, the researchers said.

Oncology drugs are a huge driver of cost, but there’s a lot of innovation happening in the space to improve care and outcomes for patients, said Michelle Booth, PharmD, director of specialty clinical solutions at Magellan Rx Management.

There are a number of trastuzumab biosimilars available, but so far there have not been any patient characteristics that have played a role in which ones are prescribed, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium.

Risankizumab, a biologic, is used for psoriasis, but whether it can improve asthma control has been unclear.

For 3 categories of evaluation, elevated cardiac troponin I levels most influenced the development of myocardial injury among persons at higher lifetime weight totals.

Use of comprehensive genomic profiling in patients with advanced non–small cell lung cancer (NSCLC) was linked with significant improvements in progression-free survival and overall survival.

Ryan Haumschild, PharmD, MS, MBA, discusses optimizing the transition to biosimilars, covering from what patients to look for as candidates to the process of switching a patient from a brand to a biosimilar to the importance of patient education.

Ryan Haumschild, PharmD, MS, MBA, continues focusing on transition optimization, explaining how to efficiently create your inventory, how his use of biosimilars will change in the future, and offering advice to those looking to transition to biosimilars.

A new review article highlights some of the newest therapies available to treat graft-versus-host disease (GVHD), but the authors say there is insufficient data to draw broad conclusions.

A pan-cancer reference atlas provides a framework for an immune-based patient stratification that study authors expect to be predictive for patient prognosis and immunotherapy response at an elevated level after further studies.

In patients refractory to conventional therapy, the combination resulted in a 70% reduction in a key biomarker compared with placebo.

Posters presented at AMCP Nexus 2021 evaluated the health care resource utilization (HRU) and costs associated with the chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.

The report suggests factors besides molecular profiling can be helpful in patient stratification.

Two abstracts presented at the CHEST Annual Meeting 2021 showed that patients with narcolepsy treated with once-nightly sodium oxybate, FT218, vs placebo exhibited significant improvements in sleep latency and cataplexy.

Angelman syndrome affects roughly 1 in every 20,000 children and it has no approved treatment.

A report suggests that people with chronic obstructive pulmonary disease (COPD) and asthma have a protein in their lungs that leaks a small molecule into their bloodstream that restricts their breathing instead of relaxing their airways.

Mortality and liver-related complications increased with fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD).

Study findings suggest that the unique genomic variations of cerebrospinal fluid can be leveraged as a liquid biopsy to effectively and safely improve decision-making regarding treatment of patients with non–small cell lung cancer (NSCLC) with leptomeningeal metastasis.

Posters presented at the AMCP Nexus 2021 meeting reviewed the cost-effectiveness and cost per response for zanubrutinib vs ibrutinib.